Search
Search Results
##search.searchResults.foundPlural##
-
PATHOBIOLOGY OF HODGKIN LYMPHOMA
3219PDF: 1430HTML: 5845Fig1-Ag-Pil: 226Ag-Pil Fig.2: 227 -
PLASMABLASTIC LYMPHOMA. A STATE-OF-THE-ART REVIEW (1) Part 1- Epidemiology, pathogenesis, clinicopathologic characteristics, differential diagnosis, prognostic factors and special populations
3550PDF: 2411HTML: 1463 -
HODGKIN LYMPHOMA IN OLDER PATIENTS: AN ORPHAN DISEASE?
2882PDF: 1360HTML: 3569Untitled: 192Untitled: 202Untitled: 177 -
PROGNOSTIC FACTORS IN HODGKIN LYMPHOMA
3313PDF: 1964HTML: 7472 -
-
FOLLICULAR LYMPHOMA: THE MANAGEMENT OF ELDERLY PATIENT
4423PDF: 1636HTML: 3617Tables and Images: 219 -
EBV-RELATED LYMPHOPROLIFERATIVE DISEASES: A REVIEW IN LIGHT OF NEW CLASSIFICATIONS EBV-RELATED LYMPHOPROLIFERATIVE DISEASES
4102PDF: 1587HTML: 952 -
PEDIATRIC HODGKIN LYMPHOMA IN LOW- and MIDDLE-INCOME COUNTRIES (LMICs). A NARRATIVE REVIEW Pediatric Hodgkin's lymphoma in low-income countries
1263PDF: 872HTML: 282 -
AUTOLOGOUS STEM CELL TRANSPLANTATION FOR AGGRESSIVE LYMPHOMAS
2544PDF: 869HTML: 2122 -
ADVANCED HODGKIN LYMPHOMA: A NEW ERA OF THERAPY
2134PDF: 1322HTML: 3501 -
-
EPIDEMIOLOGICAL OVERVIEW OF HODGKIN LYMPHOMA ACROSS THE MEDITERRANEAN BASIN
3531PDF: 1177HTML: 4998Incidence age-standardized rates for HL across the Mediterranean basin: 201 -
I INCREASED RISK OF LYMPHOMA IN MEN INFECTED WITH TUBERCULOSIS
1144PDF: 475HTML: 318 -
INFECTIONS AND FOLLICULAR LYMPHOMA: IS THERE A LINK?
3226PDF: 1008HTML: 2024 -
THE EVOLVING ROLE OF RADIOTHERAPY IN EARLY STAGE HODGKIN’S LYMPHOMA
2218PDF: 940HTML: 6783Figure 1: 170 -
ROLE OF HEMATOPOIETIC STEM CELL TRANSPLANTATION
2023PDF: 799HTML: 1045 -
FDG-PET SCAN: A NEW PARADIGM FOR FOLLICULAR LYMPHOMA MANAGEMENT.
3316PDF: 1237HTML: 2199 -
IS THERE A ROLE FOR MINIMAL RESIDUAL DISEASE MONITORING IN FOLLICULAR LYMPHOMA IN THE CHEMO-IMMUNOTHERAPY ERA?
3366PDF: 1280HTML: 2215Fi.1 Gritti.Rambaldi: 205 -
Follicular Lymphoma: A Clinicopathological Analysis from a Tertiary care Institute in Southern India
3191PDF: 778HTML: 2947Figure 1a and 1b: 147Figure 2: 159Figure 3: 176Figure 4: 158Figure 5: 162Tables 1-5: 151 -
THERAPY-RELATED MYELOID NEOPLASM IN NON-HODGKIN LYMPHOMA SURVIVORS
2579PDF: 738HTML: 2297 -
IMMUNOLOGICAL DEREGULATION IN HODGKIN’S DISEASE
2216PDF: 964HTML: 1897 -
HODGKIN LYMPHOMA IN CHILDREN: A 16-YEAR EXPERIENCE AT THE CHILDREN’S WELFARE TEACHING HOSPITAL OF BAGHDAD, IRAQ
1037PDF: 926Suppl. Files: 593HTML: 83 -
LIMITED STAGE FOLLICULAR LYMPHOMA: THE ROLE OF RADIATION THERAPY.
3696PDF: 1088HTML: 2294Figure 1: 211 -
OUTCOME OF PATIENTS WITH DIFFUSE LARGE B-CELL LYMPHOMA RELAPSING AFTER AUTOLOGOUS TRANSPLANT BEFORE AVAILABILITY OF CAR-T CELL TREATMENT Outcome of DLBCL patients relapsing after ASCT
1299HTML: 307PDF: 933Suppl. Files: 446 -
HHVs AND LYMPHOPROLIFERATIVE DISORDERS
1388PDF: 818HTML: 3123 -
TREATMENT OF EARLY STAGES HODGKIN LYMPHOMA DURING PREGNANCY
3554PDF: 1067HTML: 874 -
LYMPHOPROLIFERATIVE SYNDROMES ASSOCIATED WITH HUMAN HERPESVIRUS-6A AND HUMAN HERPESVIRUS-6B
3771PDF: 1483HTML: 485Figures . Eliassian: 222 -
POST-TRANSPLANT LYMPHOPROLIFERATIVE DISORDERS: ROLE OF VIRAL INFECTION, GENETIC LESIONS AND ANTIGEN STIMULATION IN THE PATHOGENESIS OF THE DISEASE
1243PDF: 473HTML: 18570Figure 1: 169Figure 2: 150Figure 3: 167Figure 4: 205Figure 5: 176 -
CYTOMEGALOVIRUS REACTIVATION IN ADULT RECIPIENTS OF AUTOLOGOUS STEM CELL TRANSPLANTATION: A SINGLE CENTER EXPERIENCE
1547PDF: 878HTML: 980figures: 178table 1: 181table2: 180table3: 181 -
IMMUNOTHERAPY FOR EPSTEIN-BARR VIRUS-RELATED LYMPHOMAS
1167PDF: 602HTML: 6798 -
CLONAL HEMATOPOIESIS: ROLE IN HEMATOLOGIC NON-HEMATOLOGIC MALIGNANCIES CLONAL HEMATOPOIESIS AND MALIGNANCIES
2956PDF: 890HTML: 1947 -
The MINI-POLATUZUMAB VEDOTINE PLUS CHP (POLA-R-CHP) VS. MINI-R-CHOP IN PATIENTS OVER 80 YEARS OF AGE WITH DIFFUSE LARGE B-CELL LYMPHOMA: A RETROSPECTIVE, PROPENSITY SCORE-MATCHED ANALYSIS STRATIFIED BY SIMPLIFIED FRAILTY SCORE PolaRCHP vs. RCHOP for older patients
1071PDF: 388HTML: 89 -
SOCIOECONOMIC STATUS IS GLOBALLY A PROGNOSTIC FACTOR FOR OVERALL SURVIVAL OF MULTIPLE MYELOMA PATIENTS; SYNTHESIS OF STUDIES AND REVIEW OF THE LITERATURE SES as prognostic factor for myeloma survival
2030PDF: 823HTML: 212







